跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ALK5 inhibitors (cancer)
首页
药物
ALK5 inhibitors (cancer)
ALK5 inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
(Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer
申请人: NEXYS THERAPEUTICS INC
优先权: 2019
US
ALK5 INHIBITOR CONJUGATES AND USES THEREOF
申请人: SYNTHIS THERAPEUTICS INC
优先权: 2020
CN
EP
US
WO
4 件公开
Methods of Treating Fibrosis, Cancer and Vascular Injuries
申请人: KIM DAE-KEE
优先权: 2011
US
2 件公开
Methods of treating fibrosis, cancer and vascular injuries
申请人: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUND
优先权: 2016
US
3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES
申请人: MERCK PATENT GMBH
优先权: 2015
CN
FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF
申请人: BISICHEM CO LTD
优先权: 2021
CN
EP
US
3 件公开
2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5
申请人: AGOMAB SPAIN S L U
优先权: 2020
CN
EP
US
WO
8 件公开
Thiazole derivative compound and application thereof
申请人: AUTOTELIC BIO INC
优先权: 2022
CN
药物
反馈